Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts.
Zein JG, Zounemat-Kerman N, Adcock IM, Hu B, Attaway A, Castro M, Dahlén SE, Denlinger LC, Erzurum SC, Fahy JV, Gaston B, Hastie AT, Israel E, Jarjour NN, Levy BD, Mauger DT, Moore W, Peters MC, Sumino K, Townsend E, Woodruff P, Ortega VE, Wenzel SE, Meyers DA, Chung KF, Bleecker ER; Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) Consortium and the the US National Heart, Lung, and Blood Institute Severe Asthma Research Program (SARP III).
Zein JG, et al.
Lancet Respir Med. 2025 Jan;13(1):35-46. doi: 10.1016/S2213-2600(24)00250-9. Epub 2024 Nov 22.
Lancet Respir Med. 2025.
PMID: 39586307
By contrast, the burden score was above the median value in 58 (28%) SARP III and 24 (27%) U-BIOPRED participants with non-severe asthma. In both cohorts, the burden score negatively correlated with lung function, asthma control, and qual …
By contrast, the burden score was above the median value in 58 (28%) SARP III and 24 (27%) U-BIOPRED participants with non-sev …